MondegarAI
Avidity Partners Management LP

Q2 2025 · 13F-HR

Avidity Partners Management LPholdings as filed

Filed 2025-08-14 · accession 0001791827-25-000007

$502.0M
Reported value
56
Positions
2025-06-30
Period end
View analyzed profile →PRO

The Brief · Avidity Partners Management LP · Q2 2025

AI · grounded in 13F

Avidity Partners Management LP established a new position in CGON valued at $38.9M. The fund also initiated new stakes in BSX for $34.5M and NTRA for $33.6M. Additional new positions include DNTH at $32.4M, EXK at $18.8M, and THC at $18.6M.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
156944100CGONCG ONCOLOGY INC$39.0M7.77%1,499,942CommonSOLE
101137107BSXBOSTON SCIENTIFIC CORP$34.6M6.89%321,800CommonSOLE
632307104NTRANATERA INC$33.7M6.71%199,300CommonSOLE
252828108DNTHDIANTHUS THERAPEUTICS INC$32.5M6.47%1,742,902CommonSOLE
30063P105EXKEXACT SCIENCES CORP$18.9M3.76%355,000CommonSOLE
88033G407THCTENET HEALTHCARE CORP$18.7M3.72%106,000CommonSOLE
252131107DXCMDEXCOM INC$18.4M3.66%210,500CommonSOLE
235851102DHRDANAHER CORPORATION$17.7M3.53%89,700CommonSOLE
433313103HNGEHINGE HEALTH INC$16.7M3.32%322,344CommonSOLE
46120E602ISRGINTUITIVE SURGIVAL INC$14.7M2.93%27,100CommonSOLE
372303206GMABGENMAB A/S$13.4M2.68%650,000CommonSOLE
759916109RGENREPLIGEN CORP$13.2M2.64%106,500CommonSOLE
883556102TMOTHERMO FISHER SCIENTIFIC INC$12.0M2.39%29,600CommonSOLE
881624209TEVATEVA PHARMACEUTICAL INDS LTD$11.6M2.30%689,500CommonSOLE
008064206JBIOJADE BIOSCIENCES INC$11.3M2.24%1,127,186CommonSOLE
71722W107PHATPHATHOM PHARMACEUTICALS INC$10.2M2.03%1,064,500CommonSOLE
91324P102UNHUNITEDHEALTH GROUP INC$10.0M1.99%32,000CommonSOLE
58155Q103MCKMCKESSON CORP$9.9M1.97%13,500CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$9.9M1.97%94,500CommonSOLE
03073E105CORCENCORA INC$9.8M1.96%32,800CommonSOLE
42226A107HQYHEALTHEQUITY INC$9.6M1.92%92,000CommonSOLE
29261A100EHCENCOMPASS HEALTH CORP$9.1M1.81%74,000CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$8.4M1.68%228,600CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$7.2M1.42%134,000CommonSOLE
68170A108OMDAOMADA HEALTH INC$7.1M1.42%390,600CommonSOLE
07373V105BEAMBEAM THERAPEUTICS INC$7.0M1.39%409,400CommonSOLE
444859102HUMHUMANA INC$6.7M1.34%27,600CommonSOLE
46489V302CATXPERSPECTIVE THERAPEUTICS INC$6.4M1.27%1,858,596CommonSOLE
68622V106OGNORGANON & CO$6.2M1.23%640,000CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$6.0M1.20%140,000CommonSOLE
457669307INSMINSMED INC$5.9M1.18%59,000CommonSOLE
558868105MDGLMADRIGAL PHARMACEUTICALS INC$5.8M1.15%19,000CommonSOLE
90400D108RAREULTRAGENYX PHARMACEUTICAL IN$5.6M1.12%154,000CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$4.9M0.98%7,477,255CommonSOLE
687604108ORKAORUKA THERAPEUTICS INC$3.9M0.79%352,124CommonSOLE
4525EP101VTLUSDIMMUNIC INC$3.9M0.78%5,615,811CommonSOLE
03969K108ARQTARCUTIS BIOTHERAPEUTICS INC$3.8M0.75%268,000CommonSOLE
26622P107DOCSDOXIMITY INC$3.7M0.73%60,000CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$3.4M0.67%107,891CommonSOLE
925050106VRNAVERONA PHARMA PLC$3.2M0.64%33,800CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$3.2M0.63%340,000CALLSOLE
N90064101QUREUNIQURE NV$2.9M0.57%207,000CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$2.8M0.56%65,000CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$2.7M0.53%32,000CommonSOLE
14149Y108CAHCARDINAL HEALTH INC$2.5M0.50%15,000CommonSOLE
82835W108SPRYARS PHARMACEUTICALS INC$2.4M0.49%140,000CommonSOLE
49372L2092KZ0KEZAR LIFE SCIENCES INC$2.3M0.46%502,600CommonSOLE
45826J105NTLAINTELLIA THERAPEUTICS INC$2.2M0.43%232,000CommonSOLE
61559X104MLTXMOONLAKE IMMUNOTHERAPEUTICS$1.8M0.37%39,000CommonSOLE
04335A105ARVNARVINAS INC$1.8M0.36%243,162CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$1.4M0.28%150,000CommonSOLE
811292200SCYXSCYNEXIS INC$829,2680.17%1,228,910CommonSOLE
48576U205KPTIKARYOPHARM THERAPEUTICS INC$579,9790.12%134,566CommonSOLE
02155H200ALTALTIMMUNE INC$406,3500.08%105,000CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$226,6780.05%11,300CommonSOLE
76152G100REVIVA PHARMACEUTICALS HOLDING$52,5920.01%138,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.